Studies in Asian women and adult population found people living with HIV switching to Biktarvy® from baseline regimen sustained viral suppression and tolerability. Read More
Gilead Sciences Presents Findings from Clinical Studies Evaluating Patients Who Switched to Biktarvy(R) at 2020 Asia Pacific AIDS & Co-infections Conference
Reading Time: < 1 minute